Skip to main content
RAPP
NASDAQ Life Sciences

Rapport Posts Q3 Loss of $40.2M, Pro Forma Cash of $815.4M and Runway Through 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$25.48
Mkt Cap
$1.221B
52W Low
$22.061
52W High
$52.93
52W Position info
15% above low
Off High info
52% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

RAPP sits 15% above its 52-week low of $22.061.

Summary

Rapport reported a wider Q3 loss of $40.2M but ended the quarter with $395.0M in cash and investments, and with October's raise it now holds about $815.4M — enough to fund operations through the end of 2029.


Key Events · Earnings and Guidance · RAPP

  • Q3 Loss Widens on Phase 3 Spend

    Net loss was $40.2M versus $26.9M a year earlier; R&D rose to $34.3M from $22.3M on the Phase 3 FOS program and completion of the bipolar mania Phase 2.

  • Pro Forma Cash of $815.4M

    $395.0M of cash, equivalents and short-term investments at September 30, 2026, plus about $420.7M of October offering and November ATM proceeds, gives roughly $815.4M.

  • Runway Extended Through 2029

    Management expects the combined cash to fund operating expenses and capital expenditures through the end of 2029.

  • Small ATM Sale at Market

    About $10M of common stock was sold in November 2026 under the existing ATM program at $25.05 per share, the prevailing market price.


Analysis · RAPP · Life Sciences

The quarter itself was a spending story: net loss widened to $40.2M from $26.9M a year ago as R&D jumped to $34.3M on the Phase 3 focal onset seizure program and the bipolar mania Phase 2. What matters more is the balance sheet — $395.0M of cash and investments at September 30, plus roughly $420.7M of October and November proceeds, gives about $815.4M and funds operations through the end of 2029. That removes any near-term financing need just as the company moves RAP-219 into two Phase 3 bipolar mania trials planned for the second half of 2027, following the positive Phase 2 readout on October 20. The only new dilution item is a small ATM sale of about $10M at $25.05 per share, done at the prevailing market price.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RAPP was trading at $25.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $22.06 to $52.93. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RAPP - Latest Insights

RAPP
Oct 30, 2026, 7:32 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $24.56
Real-time Price: $23.40 info
Change: -$1.16 (-5%) info
Market Cap: $1.387B info
RAPP
Oct 30, 2026, 5:12 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $25.56
Real-time Price: $23.40 info
Change: -$2.16 (-8%) info
Market Cap: $1.387B info
RAPP
Oct 30, 2026, 7:04 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $22.55
Real-time Price: $23.40 info
Change: +$0.850 (+4%) info
Market Cap: $1.387B info
RAPP
Oct 28, 2026, 6:18 AM EDT
Filing Type: FWP
Importance Score:
8
Price at Filing: $21.80
Real-time Price: $23.40 info
Change: +$1.60 (+7%) info
Market Cap: $1.387B info
RAPP
Oct 28, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $22.31
Real-time Price: $23.40 info
Change: +$1.09 (+5%) info
Market Cap: $1.387B info